FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

[10-22-2015] The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause severe liver injury mostly in patients with underlying advanced liver disease.

Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news